News & Events

Press Releases

Show All

September 2010

September 16, 2010 Cellular Dynamics International, ACEA Biosciences, and Roche Applied Sciences Cooperate to Evaluate iCell Cardiomyocytes on the xCELLigence SystemDownload PDF

MADISON, Wis., Sep 16, 2010 – Cellular Dynamics International (CDI) announced today their partnership with ACEA Biosciences to bring early and accurate prediction of potential cardiotoxic side effects to the drug discovery process. The partnership combines CDI’s induced pluripotent stem cell (iPSC)-derived heart cells, iCell® Cardiomyocytes, with the xCELLigence™ RTCA System. The xCELLigence System is developed by ACEA and Roche Applied Science (SIX: RO, ROG; OTCQX: RHHBY) and marketed by Roche.